Tolmar Launches New Laboratory at Rosalind Franklin University

Tolmar, Inc., a specialty pharmaceutical company, has officially opened its new Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park (IRP) in North Chicago, Illinois. This new facility marks a significant expansion of Tolmar’s capacity for developing and commercializing pharmaceutical products, further strengthening the university’s ecosystem of industry innovation.

Founded in 2007, Tolmar is internationally recognized for its advanced long-acting injectable drug delivery capabilities. The company specializes in manufacturing products in urology, oncology, and endocrinology. Its leading product is utilized in the treatment of advanced prostate cancer and is marketed in 89 countries globally.

The establishment of this research facility at Rosalind Franklin’s IRP aligns with Tolmar’s goal to enhance its product development capabilities. The new lab will complement the company’s existing operations in Northern Colorado, where a robust team of researchers and engineers is already engaged in innovative pharmaceutical work.

Dr. Dave Loffredo, vice president of innovation at Tolmar, expressed enthusiasm about the new venture. “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois,” he stated. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”

The new lab is strategically located within a vibrant network of life science companies in Lake County, which provides ample opportunities for collaboration. Dr. Stace Porter, senior vice president of development operations for Tolmar, emphasized the benefits of this location. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores.”

The IRP itself is a state-of-the-art facility, spanning 100,000 square feet and housing six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, executive vice president for research at RFU, welcomed Tolmar to the university’s community. “We look forward to collaborations that can help accelerate new product development,” he said. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”

As Tolmar establishes its new laboratory, the collaboration with Rosalind Franklin University is expected to enhance research capabilities and foster advancements in pharmaceutical development. The partnership may lead to significant breakthroughs in treatments for various medical conditions, benefiting patients worldwide.

For more information about Tolmar, visit their official website at www.tolmar.com. To learn more about Rosalind Franklin University, please visit rosalindfranklin.edu.